Department of Gynecology, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 271199, China.
Obstetrics and Gynecology Department, The second children & women's healthcare of jinan city, Jinan, Shandong 271199, China.
Pharmacol Res. 2021 Jul;169:105612. doi: 10.1016/j.phrs.2021.105612. Epub 2021 Apr 16.
Inconsistencies exist with regard to influence of tibolone treatment on the lipid profile. The reasons for these inconsistencies might derive from several factors, i.e., differences in baseline variables, intervention duration, participants' health status or baseline body mass index (BMI). To address these inconsistencies, based on a systematic search in Scopus, PubMed/Medline, Web of Science, and Embase for papers published until 21 December 2020, we conducted the current dose-response meta-analysis of randomized controlled trials (RCTs) to determine the impact of tibolone treatment on the lipid profile. The overall findings were derived from 26 RCTs. Tibolone administration decreased total cholesterol (TC) (weighted mean difference, WMD: -18.55 mg/dL, CI: -25.95 to -11.16, P < 0.001), high-density lipoprotein-cholesterol (HDL-C) (WMD: -9.42 mg/dL, CI: -11.83 to -7.01, P < 0.001) and triglyceride (TG) (WMD: -21.43 mg/dL, CI: -27.15 to -15.70, P < 0.001) levels. A significant reduction in LDL-C occurred when tibolone was prescribed for ≤ 26 weeks (WMD: -7.64 mg/dL, 95% CI: -14.58 to -0.70, P = 0.031) versus > 26 weeks (WMD: -8.84 mg/dL, 95% CI: -29.98, 12.29, P = 0.412). The decrease in TG (WMD: -22.64 mg/dL) and TC (-18.55 mg/dL) concentrations was more pronounced in patients with BMI ≥ 25 kg/mversus BMI < 25 kg/m. This systematic review and meta-analysis discovered that tibolone decreases TC, HDL-C and TG levels. LDL-C concentrations are significantly reduced when tibolone administration lasts for ≤ 26 weeks.
关于替勃龙治疗对血脂谱的影响存在不一致之处。这些不一致的原因可能源于几个因素，例如，基线变量、干预持续时间、参与者的健康状况或基线体重指数（BMI）的差异。为了解决这些不一致的问题，我们基于对 Scopus、PubMed/Medline、Web of Science 和 Embase 中截至 2020 年 12 月 21 日发表的论文的系统搜索，进行了当前的替勃龙治疗随机对照试验（RCT）的剂量反应荟萃分析，以确定替勃龙治疗对血脂谱的影响。总体结果来自 26 项 RCT。替勃龙治疗可降低总胆固醇（TC）（加权均数差，WMD：-18.55mg/dL，CI：-25.95 至-11.16，P<0.001）、高密度脂蛋白胆固醇（HDL-C）（WMD：-9.42mg/dL，CI：-11.83 至-7.01，P<0.001）和甘油三酯（TG）（WMD：-21.43mg/dL，CI：-27.15 至-15.70，P<0.001）水平。当替勃龙的处方时间≤26 周时，LDL-C 水平显著降低（WMD：-7.64mg/dL，95%CI：-14.58 至-0.70，P=0.031），而>26 周时（WMD：-8.84mg/dL，95%CI：-29.98，12.29，P=0.412）。在 BMI≥25kg/m 的患者中，TG（WMD：-22.64mg/dL）和 TC（WMD：-18.55mg/dL）浓度的降低更为明显。与 BMI<25kg/m 的患者相比。这项系统评价和荟萃分析发现，替勃龙可降低 TC、HDL-C 和 TG 水平。当替勃龙的给药时间≤26 周时，LDL-C 浓度显著降低。
